Professeure agrégée de clinique
 |
CoordonnéesCentre Hospitalier Universitaire Sainte-Justine |
.T 514 345-4931 poste 7988 |
Thèmes
Cellules souches cancéreuses et métalloprotéases dans le neuroblastome. Détermination des intervalles de référence pédiatriques pour différents biomarqueurs sériques. Membre du groupe CALIPER (Canadian Initiative in Pediatric Reference Intervals). Déterminations des intervalles de référence pour différents biomarqueurs sériques durant la grossesse (Étude Mère-Enfant). Développement, évaluation et validation de méthodes d’analyses de biomarqueurs biochimiques. |
||
Publications récentes
Delvin E, Alos N, Rauch F, Marcil V, Morel S, Boisvert M, Lecours MA, Laverdière C, Sinnett D, Krajinovic M, Dubois J, Drouin S, Lefebvre G, Samoilenko M, Nyalendo C, Cavalier E, Levy E. (2018) Vitamin D nutritional status and bone turnover markers in childhood acute lymphoblastic leukemia survivors: A PETALE study. Clin Nutr. pii: S0261-5614(18)30069-4
Belounis A, Nyalendo C, Le Gall R, Imbriglio TV, Mahma M, Teira P, Beaunoyer M, Cournoyer S, Haddad E, Vassal G, Sartelet H. (2016) Autophagy is associated with chemoresistance in neuroblastoma. BMC Cancer, 16(1):891.
Liberman J, Sartelet H, Flahaut M, Mühlethaler-Mottet A, Coulon A, Nyalendo C, Vassal G, Joseph JM, Gross N. (2012) Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma. PLoS One, 7(8):e43665.
Sartelet H, Imbriglio T, Nyalendo C, Haddad E, Annabi B, Duval M, Fetni R, Alexendrov L, Sinnett D, Fabre M, Vassal G. (2011) Expression of CD133 and poor outcome in neuroblastoma associated with chemoresistance mediated by AKT pathway. Histopathology, 60(7):1144-55.
Sartelet H, Durrieu L, Fontaine F, Nyalendo C, Haddad E. (2012) Description of a new xenograft model of metastatic neuroblastoma using NOD/SCID/Il2rg Null (NSG) mice. In Vivo, 26(1):19-29.
Nyalendo C, Sartelet H, Gingras D, Béliveau R. (2010) Inhibition of membrane-type 1 matrix metalloproteinase tyrosine phosphorylation blocks tumor progression in mice. Anticancer Res, 30(6):1887-95.
Nyalendo C, Sartelet H, Barette S, Ohta S, Gingras D, Béliveau R. (2009) Identification of phosphorylated membrane-type 1 matrix metalloproteinase in association with neuroblastoma progression. BMC Cancer, 9(1):422.
Nyalendo C, Beaulieu E, Sartelet H, Michaud M, Fontaine N, Gingras D, and Béliveau R. (2008) Impaired tyrosine phosphorylation of membrane type 1-matrix metalloproteinase reduces tumor cell proliferation in three-dimensional matrices and abrogates tumor growth in mice. Carcinogenesis, 29(8): 1655–64.
Nyalendo C, Michaud M, Beaulieu E, Roghi C, Murphy G, Gingras D, and Béliveau R. (2007) Src-mediated phosphorylation of membrane-type 1 matrix metalloproteinase on its residue tyrosine 573: role in endothelial and tumour cell migration. J Biol Chem, 282(21): 156690-9.